CUI Global, Inc. (CUI) At $2.58 Forms Bottom; 8 Bullish Analysts Covering Intersect ENT, Inc. (XENT)

Intersect ENT, Inc. (NASDAQ:XENT) Logo

Among 10 analysts covering Intersect ENT (NASDAQ:XENT), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Intersect ENT had 21 analyst reports since August 17, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Tuesday, January 2 by JP Morgan. The stock has “Buy” rating by Deutsche Bank on Wednesday, August 2. Piper Jaffray maintained the shares of XENT in report on Tuesday, September 29 with “Overweight” rating. The stock of Intersect ENT, Inc. (NASDAQ:XENT) has “Buy” rating given on Monday, August 21 by Piper Jaffray. As per Thursday, October 1, the company rating was maintained by Canaccord Genuity. The firm has “Buy” rating by J.P. Morgan given on Wednesday, May 2. The rating was maintained by Northland Capital on Wednesday, August 2 with “Hold”. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, December 6 report. The firm has “Outperform” rating by Northland Capital given on Tuesday, March 29. The stock of Intersect ENT, Inc. (NASDAQ:XENT) has “Hold” rating given on Thursday, October 6 by Deutsche Bank. See Intersect ENT, Inc. (NASDAQ:XENT) latest ratings:

02/05/2018 Broker: J.P. Morgan Rating: Buy New Target: $48.0000 Maintain
04/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $43.0 Maintain
02/01/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
06/12/2017 Broker: Canaccord Genuity Rating: Buy New Target: $36.0 Maintain
06/11/2017 Broker: BTIG Research Rating: Hold

CUI Global, Inc. (CUI) formed multiple bottom with $2.48 target or 4.00% below today’s $2.58 share price. CUI Global, Inc. (CUI) has $73.49M valuation. The stock decreased 1.90% or $0.05 during the last trading session, reaching $2.58. About 28,923 shares traded. CUI Global, Inc. (NASDAQ:CUI) has declined 38.67% since May 5, 2017 and is downtrending. It has underperformed by 50.22% the S&P500.

Among 6 analysts covering CUI Global (NASDAQ:CUI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CUI Global has $12.0 highest and $600 lowest target. $8.50’s average target is 229.46% above currents $2.58 stock price. CUI Global had 7 analyst reports since December 23, 2015 according to SRatingsIntel. The company was maintained on Wednesday, May 11 by Dougherty & Company. The rating was initiated by FBR Capital with “Buy” on Tuesday, April 17. The firm has “Buy” rating given on Thursday, August 10 by H.C. Wainwright. Dougherty & Company maintained CUI Global, Inc. (NASDAQ:CUI) rating on Friday, November 11. Dougherty & Company has “Buy” rating and $7.0 target. Rodman & Renshaw initiated the shares of CUI in report on Wednesday, December 23 with “Buy” rating.

Analysts await CUI Global, Inc. (NASDAQ:CUI) to report earnings on May, 9. They expect $-0.09 EPS, up 47.06% or $0.08 from last year’s $-0.17 per share. After $-0.07 actual EPS reported by CUI Global, Inc. for the previous quarter, Wall Street now forecasts 28.57% negative EPS growth.

Investors sentiment increased to 2 in 2017 Q4. Its up 1.36, from 0.64 in 2017Q3. It increased, as 1 investors sold CUI Global, Inc. shares while 9 reduced holdings. 10 funds opened positions while 10 raised stakes. 14.82 million shares or 29.77% more from 11.42 million shares in 2017Q3 were reported. Tower Research Ltd Liability Co (Trc) holds 956 shares or 0% of its portfolio. Heartland Advsrs stated it has 0.43% of its portfolio in CUI Global, Inc. (NASDAQ:CUI). 842,616 were reported by White Pine Cap Ltd Liability. Dimensional Fund Advisors L P holds 0% or 26,080 shares. Barclays Public Limited Liability Corp reported 91 shares. Bessemer Group Inc holds 0% in CUI Global, Inc. (NASDAQ:CUI) or 16,000 shares. 14,505 are owned by Van Den Berg Mgmt I. Perkins Inc owns 0.56% invested in CUI Global, Inc. (NASDAQ:CUI) for 212,450 shares. Blackrock Incorporated reported 0% of its portfolio in CUI Global, Inc. (NASDAQ:CUI). M&R Cap Management stated it has 0.01% of its portfolio in CUI Global, Inc. (NASDAQ:CUI). Moreover, Wealthtrust Axiom Ltd Llc has 0.46% invested in CUI Global, Inc. (NASDAQ:CUI) for 450,657 shares. Renaissance Techs Ltd Liability Corp reported 0% stake. 61,349 were accumulated by Northern Tru. Moreover, Clear Harbor Asset Lc has 0.6% invested in CUI Global, Inc. (NASDAQ:CUI) for 1.17M shares. Geode Capital Management Lc owns 114,041 shares for 0% of their portfolio.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company has market cap of $1.26 billion. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It currently has negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

The stock increased 2.96% or $1.2 during the last trading session, reaching $41.7. About 245,864 shares traded or 7.39% up from the average. Intersect ENT, Inc. (NASDAQ:XENT) has risen 124.86% since May 5, 2017 and is uptrending. It has outperformed by 113.31% the S&P500.

More news for Intersect ENT, Inc. (NASDAQ:XENT) were recently published by: Streetinsider.com, which released: “Intersect ENT (XENT) Tops Q1 EPS by 3c, Beats on Revenues” on May 01, 2018. Nasdaq.com‘s article titled: “Investor Expectations to Drive Momentum within AMN Healthcare Services, Cass Information, William Lyon Homes …” and published on April 24, 2018 is yet another important article.

CUI Global, Inc. (NASDAQ:CUI) Institutional Positions Chart